Disease Areas
William Blair Initiates Coverage of MDxHealth With Outperform Rating
A letter to investors noted the company's dedicated focus on prostate cancer diagnostics, which de-risks the firm's growth outlook and path to profitability.
The company's next-generation sequencing-based test detects more than 400 recurrent alterations that can identify 96 percent of bladder cancers.
Medulloblastoma Long-Read Sequences Reveal Complex Rearrangements, Methylation Changes
With Oxford Nanopore sequencing, researchers found DNA methylation clues and complex rearrangement patterns that were subsequently assessed in a broader cancer set.
Onconova Therapeutics, Pangea Biomed Collaborate on AI-Driven Cancer Biomarker Study
The companies will apply Pangea's ENLIGHT platform to map gene interactions in pathways modulated by Onconova's investigational cancer therapy rigosertib.
Genetic Risk of Substance Use Disorders Untangled in Large-Scale GWAS Meta-Analysis
The study, of over 1 million individuals with European ancestry and almost 100,000 of African descent, found loci associated with general and substance-specific addiction.